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Effects of intradermal injection of atrial natriuretic peptide
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Department of Medicine, Respiratory Division, Royal Postgraduate Medical School, Hammersmith Hospital,
Du Cane Road, London, W12 ONN
Atrial natriuretic peptide (ANP) causes mast cell degranulation in rats in vivo and in
vitro but is bronchodilator in humans. The aim of this study was to investigate the
wheal and flare dose-response to intradermal injection of a-human ANP in normal
humans. Eight normal subjects received five 30 gl injections containing 1, 10, 39, 78,
117 pmol ANP and one each of normal saline, histamine 675 pmol and substance
P 30 pmol. Maximum ANP flare response was greater but not significantly than that
to saline at 1.55 ± 0.6 (mean ± s.e. mean) compared with 0.42 ± 0.17 cm2, but much
less than to histamine 9.86 ± 0.97 or to substance P 12.5 ± 1.2. Maximum ANP wheal
response was significantly greater than that to saline at 0.38 ± 0.08 compared with
0.18 ± 0.05 cm2 (difference between means 0.20, 95% CI 0.05, 0.35), but much less
than to histamine 0.75 ± 0.06 or to substance P 1.05 ± 0.08 cm2. No dose-response to
ANP was demonstrated, though responses to the highest dose differed significantly
from those to the lowest dose studied. We conclude that human cutaneous responses
to ANP differ from those of animals and that the skin is less responsive than other
tissues in humans.
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Introduction Methods
Human ANP is a 28 amino acid peptide hormone
with vasodilator, natriuretic and diuretic properties
which has recently been shown to have broncho-
dilator activity when given by infusion [1] or inhala-
tion [2]. However, in vitro ANP has recently been
shown to release histamine from rat peritoneal mast
cells and to increase rat skin vascular permeability in
vivo over a 3-4 log dose range [3]. Other peptides
such as substance P and other tachykinins release
histamine from mast cells in vitro and lead to cut-
aneous wheal and flare responses in man [4]. If ANP
caused mast cell degranulation in humans then it
would be expected to have adverse consequences
when administered to asthmatic patients. The aim of
this study was to examine whether injection of human
ANP causes cutaneous mast cell responses in normal
volunteers.
In this preliminary study we tested the hypothesis
that ANP induces wheal and flare responses in a
dose-dependent manner in human skin similar to its
effect in animals. We compared responses with those
elicited by previously selected doses of substances P
and histamine [5].
Eight normal subjects, mean age 37 (range 30-45)
years, were studied on one occasion. The study was
approved by the Ethics Committee of the Royal Post-
graduate Medical School and Hammersmith Hospital,
and all volunteers gave written informed consent.
Intradermal injections were made in a volume of
30 gl with a 29 gauge needle. Stock solutions of a-
human ANP (Bachem Inc, Torrance-California),
3.25 x 10-5 M in distilled water and substance P
0.1 mm (Sigma, Poole, UK) in 17 mm acetic acid in
isotonic saline were prepared [5]. Final dilutions of
ANP, substance P and histamine acid phosphate were
made in sterile isotonic saline immediately before use.
Five intradermal injections of 30 pl ANP 3.25 x
108, 3.25 x 10-7, 1.3 x 10-6, 2.6 x 10-6, 3.9 x 10-6 M
(containing 1, 10, 39, 78, 117 pmol) and one each of
saline, histamine 2.25 x 10-5 M (675 pmol) and sub-
stance P 1 X 10-6 M (30 pmol) were given coded and
in random order. Four injections were given to each
forearm. Both subject and observer recording the
results were unaware of the code. Flare area and
wheal area were outlined with a ball-point pen at 5
and 15 min respectively. A permanent record was
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made by transferring the outline onto 1 mm graph
paper using transparent adhesive tape (Sellotape).
Statistical methods
Results were expressed as mean ± s.e. mean (unless
otherwise indicated). Non-parametric Wilcoxon signed
rank tests were used to compare changes in flare and
wheal surface area between treatments. A value of
P < 0.05 was considered statistically significant.
Results
The intradermal injections of saline and ANP caused
transient discomfort lasting less than 10 s in all sub-
jects. Histamine and substance P caused pain and itch
in six subjects. Subjects did not distingush injections
containing ANP from others. No systemic side effects
occurred. Flare responses (mean ± s.e. mean) to ANP
1, 10, 39, 78 and 117 pmol were 0.33 ± 0.11, 0.70 ±
0.26, 0.52 ± 0.14, 0.68 ± 0.20 and 1.55 ± 0.57 cm2
and wheal responses were 0.22 ± 0.05, 0.21 ± 0.06,
0.22 ± 0.06, 0.27 ± 0.08 and 0.38 ± 0.08 cm2, respec-
tively. There were no significant differences between
ANP 1, 10, 39, and 78 pmol and saline control, but
maxifnum ANP wheal response was significantly
greater than that to saline (difference between means
0.20, 95% CI 0.05, 0.35, P < 0.05). Flare and wheal
responses to maximum ANP were significantly
greater than those to ANP 1 pmol; difference between
means 1.22, 95% CI 0.13, 2.31 for flare (P < 0.02)
and 0.16, 95% CI 0.03, 0.24 cm2 for wheal (P <
0.05). Flare and wheal responses were 9.86 ± 0.97
and 0.75 ± 0.06 cm2 for histamine and 12.5 ± 1.2 and
1.05 ± 0.08 cm2 for substance P. These responses
were significantly greater than those to ANP (P <
0.02, Figure 1).
Discussion
This is the first study to report the effects of intra-
dermal a-human ANP in man. Small flare and wheal
responses were produced. Only the wheal response to
the highest dose of ANP differed significantly from
that to saline. Similarly, only flare and wheal
responses to the highest dose of ANP differed from
those to the lowest dose (2 log units less). Thus, we
failed to define a dose-response in this preliminary
study. Cost has so far prohibited the use of higher
doses of ANP.
The highest concentrations of ANP used were four-
fold greater than those producing increased per-
meability in rat skin (1 x 10-6 M) [3]. Furthermore
dose-dependent histamine release from rat isolated
peritoneal mast cells in vitro occurs with atrial pep-
tides [ANP(1-28), ANP(3-28) and ANP(5-28)] at
concentrations starting at 1 x 10-7 M [3]. Finally, high
dose infusion of ANP in man produced respiratory,
metabolic and marked cardiovascular responses at
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Figure 1 a) Flare and b) wheal response areas in cm2
(mean ± s.e. mean) to intradermal injection of 30 gl normal
saline (0.9%), histamine (675 pmol), substance P (30 pmol)
and ANP (1, 10, 39, 78, 117 pmol).
serum concentrations of 5.7 x 10-8 - 9.6 x 10-7 M
[1]. Infusion of similar doses produced significant
changes in cutaneous blood flow [6, 7]. It is unclear
why human skin appears less responsive to ANP than
other tissues but this may relate to enhanced activity
of cutaneous endopeptidases.
We obtained significantly greater cutaneous re-
sponses to histamine and substance P, although the
molar concentrations of ANP used were comparable.
Responses to histamine and substance P were similar
to those obtained by Foreman et al. [4] and ourselves
in a previous study [5]. We measured wheal area as
opposed to volume, but previous work has shown
good correlation between the two [8] and it is un-
likely that our findings would have been altered by
determination of skin thickness.
It is possible that different forms of ANP might
have different activities but a-human ANP appears
the most relevant for study in man and was the most
active in vitro [3]. It is unclear to what extent human
cutaneous mast cell responses depend on specific
receptors and to what extent they are determined by
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the peptides basic nature [4]. We have shown that
the response in humans is reduced compared with
that in rats. Furthermore, cutaneous wheal and flare
responses are minimal at ANP concentrations which
elicit marked cardiovascular effects in humans [1].
The dose-dependent bronchodilator effects of ANP in
animals [9, 10] and humans [1, 2, 11, 12], without
any suggestion of pulmonary mast cell degranulation,
are consistent with our finding of reduced mast cell
response to ANP in human skin in vivo.
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